Register for our free email digests:
Latest From QuatRx Pharmaceuticals Co.
Keeping Track: FDA Approves First Rx DHEA, Receives Applications For Midostaurin, Gesulkumab, Biosimilar Avastin
The latest drug development news and highlights from our FDA Performance Tracker.
Viking Therapeutics licensed five assets from Ligand Pharmaceuticals, including a clinical-stage type 2 diabetes program that the private San Diego-based company has been working on since it was founded in late 2012.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing.
Big Pharma’s exodus from women’s health has created opportunities for biotech start-ups, which hope to tap into potentially huge markets. Profiles of Evestra Pharmaceuticals, S1 Biopharma, and Sprout Pharmaceuticals.
- Implantable Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Therapeutic Areas
- Metabolic Disorders
- North America
- Parent & Subsidiaries
- EnteroMedics Inc.
- Senior Management
Dan Gladney, Pres. & CEO
Scott Youngstrom, CFO & COO
Scott A Shikora, MD, CMO
Paul Hickey, SVP, Mktg. & Reimbursement
Peter Delange, SVP, Ops. & Bus. Dev.
Nick A Ansari, SVP, Sales
- Contact Info
Phone: (651) 634-3003
2800 Patton Rd.
St. Paul, MN 55113
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.